Gonadotropin Releasing Hormone Agonist for Luteal Phase Support in Gonadotropin Releasing Hormone Antagonist Protocol Cycles
Who is this study for? Patients with Infertility
What treatments are being studied? Triptorelin
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
Evaluation of the effect of adding a single dose of gonadotropin releasing hormone agonist (GnRHa) as a luteal phase support on the outcomes of intracytoplasmic sperm injection (ICSI) following GnRH antagonist protocol
Eligibility
Participation Requirements
Sex: Female
Minimum Age: 20
Maximum Age: 38
Healthy Volunteers: f
View:
• Women subjected to ICSI through controlled ovarian hyperstimulation (COH) with pituitary downregulation by GnRH antagonist.
Locations
Other Locations
Egypt
Fertility Care Unit (FCU) in Mansoura University Hospital
RECRUITING
Al Mansurah
Private fertility care centers
RECRUITING
Al Mansurah
Contact Information
Primary
Mohamed S Abdelhafez, Dr
msabdelhafez@gmail.com
+201144523366
Time Frame
Start Date: 2016-08-07
Estimated Completion Date: 2024-12-31
Participants
Target number of participants: 200
Treatments
Active_comparator: GnRHa group
Luteal phase SC administration of a single dose (0.2 mg) of GnRHa (Triptorelin)
No_intervention: Control group
No GnRHa administration in luteal phase
Related Therapeutic Areas
Sponsors
Leads: Mansoura University